



Danny Rischin

Contact

Danny Rischin

Publications (5)

Harrington K, Burtneß B, Greil R, Soulières D, Tahara M, de Castro G, Psyrrí A, Brana I, Basté N, Neupane P, Bratland Å, Fueeder T, Hughes B, Mesia R, Ngamphaiboon N, Rordorf T, Wan Ishak W, Lin J, Gumuscu B, Swaby R, Rischin D. Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study. *J Clin Oncol* 2022;JCO2102508.

Rischin D, Harrington K, Greil R, Soulières D, Tahara M, de Castro G, Psyrrí A, Brana I, Neupane P, Bratland Å, Fueeder T, Hughes B, Mesia R, Ngamphaiboon N, Rordorf T, Ishak W, Hong R, Mendoza R, Jia L, Chirovsky D, Norquist J, Jin F, Burtneß B. Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048. *Oral Oncol* 2022; 128:105815.

Burtneß B, Rischin D, Greil R, Soulières D, Tahara M, de Castro G, Psyrrí A, Brana I, Basté N, Neupane P, Bratland Å, Fueeder T, Hughes B, Mesia R, Ngamphaiboon N, Rordorf T, Wan Ishak W, Ge J, Swaby R, Gumuscu B, Harrington K. Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score. *J Clin Oncol* 2022; 40:2321-2332.

Burtneß B, Harrington K, Greil R, Soulières D, Tahara M, de Castro G, Psyrrí A, Basté N, Neupane P, Bratland Å, Fueeder T, Hughes B, Mesia R, Ngamphaiboon N, Rordorf T, Wan Ishak W, Hong R, González Mendoza R, Roy A, Zhang Y, Gumuscu B, Cheng J, Jin F, Rischin D. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. *Lancet* 2019; 394:1915-1928.

Au-Yeung G, Etemadmoghadam D, Drapkin R, Karst A, Rischin D, Mileskin L, Pearson R, Cullinane C, Aziz D, Lackovic K, Jarman K, Mitchell C, Azar W, Winder F, Bowtell D. Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition. *Clin Cancer Res* 2017; 23:1862-1874.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch